Announcing the acquisition of Asymptote by GE Healthcare
Asymptote is pleased to announce that we are now part of GE Healthcare. The acquisition means Asymptote can reach a larger audience through the GE Cell Therapy specialist team, gives us a stronger platform for our new product launches, and the ability to significantly scale up our product pipeline. Read full press release
One month to go! Looking forward to seeing you at ISCT on 3-6 May
Asymptote will be at ISCT demonstrating our complete cryochain technology (booth no. 419), addressing the challenges of the cryogenic cold chain in the main educational programme and presenting posters on the latest scientific advances in cell thawing.
New career opportunities at Asymptote
Showcasing our work at the Parliamentary Office of Science and Technology, January 2017
Asymptote and the Cell and Gene Therapy Catapult will be attending the Science, Innovation and the UK Industrial Strategy meeting at the House of Parliament on 26 January to demonstrate the outcome of our collaboration over the last two years. We will display our range of automated thawing systems which thaw cell-based therapies under Good Manufacturing Practice (GMP) conditions.
Meet up at Phacilitate’s Cell and Gene Therapy World, January 2017
Dr Stuart Milne, our CTO, will be representing Asymptote at Phacilitate this year. With the recent launches of the CellSeal Automated Thawing System and the my.Cryochain platform and an exciting year ahead, we have lots to talk about. Please contact firstname.lastname@example.org to schedule a meeting with Stuart.
Medical device regulatory milestone passed!
Just whilst everyone was packing up for Christmas, Asymptote successfully passed Stage 1 of the International Organization of Standardization (ISO) standard 13485. Asymptote is on its way towards ISO certification to show that we have a comprehensive quality management systems in place to successfully design and manufacture medical devices. We have more assessment stages scheduled and will bring you more news as we progress.
29 November 2016
Introducing the CellSeal Automated Thawing System
Cook Regentec and Asymptote announced today the commercial launch of the CellSeal Automated Thawing System for effective, fully automated thawing in lab. Please read the press release for further information.
29-30 November 2016
Meet us at the Cell and Gene Therapy Manufacturing Congress
Dr John Morris will present on the “Challenges controlling thawing at remote sites and other cryochain headaches” at 3:10pm on Tuesday 30 November at the Cell and Gene Therapy Manufacturing Congress in Amsterdam.
Asymptote will be present throughout the meeting on Stand number 41.
28 November 2016
my.Cryochain now available
Asymptote introduces the my.Cryochain software platform to control the cryogenic cold chain for cellular therapies. Announced today: the commercial launch of my.Cryochain, a software platform developed specifically to give centralized control of the cryogenic cold chain for cellular therapies. Please read the press release for further information.
2-3 November 2016
Dr Peter Kilbride presented at the International Alliance for Biological Standardization (IABS) on Key issues in the development of improved preservation and storage. View the presentation.
22 October 2016
Asymptote demonstrated prototypes of our new cryobag and cryovial thawers at the AMC’s 13th Technical Meeting in London.
16 October 2016
Dr Stuart Milne presented at the ELRIG Drug Discovery meeting in Liverpool, speaking on the topic of "Point of care thawing of cryopreserved cell therapies".
7 September 2016
Dr John Morris presented two papers at the International Institute of Refrigeration (IIR) workshop on “Cold Applications in Life Science.”
23-27 July 2016
Dr Peter Kilbride presented three papers at the Annual Meeting of the Society for Cryobiology, in Ottawa. The University of Leeds and Loughborough University also presented papers developed in collaboration with Asymptote at this event.
We are pleased to announce that Peter Kilbride, PhD student at Asymptote as been awarded his PhD by University College London.
After completing his undergraduate degree in Physics at Kings College London, Peter went on to start his PhD at University College London, in the Division of Medicine, Institute of Liver and Digestive Health with his specialist field being mathematics and low temperature biology. He investigated scale-up cryopreservation from 2ml to 2 litre biomass for use with a bioartificial Liver system. The title of his PhD was ‘Experimental and Mathematical modelling of the culturing and cryopreservation of a bioartificial liver device utilising a 3D cell scaffold construction.” Working as a cryobiologist for Asymptote, Dr. Kilbride is now working on plenty of upcoming exciting projects. In collaboration with CABI (Commonwealth Agriculture Bank) and the University of Ghana , Dr. Kilbride is developing new methods to freeze dry natural non chemical pesticides for use in underdeveloped countries. About to launch in July is a project to investigate novel methods to cryopreserve large volumes to vitrify complex tissues using non-Newtonian fluids, in partnership with the Mathematics Department at UCL. To read more about Dr. Kilbride’s work, you can view the following publications:
Returning to normal life after completing his thesis, Dr. Kilbride is looking forward to getting married in August of this year.
Successful showcase for Asymptote at the 2016 Stem Cell and Regenerative Medicine Congress, London.
Asymptote enjoyed a busy time at this years Stem Cell and Regenerative Medicine congress. We were keen to demonstrate machines from the ViaFreeze range, along with our new developments in thawing devices with solutions for cryobags and cryovials. The stand attracted plenty of interest with lots of visitors asking about thawing and end-to-end monitoring within the cryochain. The ViaThaw prototype for cryobags was put through its paces with attendees trying out the unique flexible bed. Dr. Chris Creasey, CSO, demonstrated the control offered by our freezers using infrared camera technology to display in real-time what was happening inside the freezer.
Following the event it’s back to the labs where we are working to preparing the first of our thawing products for launch before the end of this year.
Asymptote and the Cell and Gene Therapy Catapult announce licensing agreement for thawing cell-based therapies.
John Morris is an invited speaker at the first global summit on “The Grand Challenges in Organ Preservation,” to be held in Silicon Valley, February 26-28, 2015.
Asymptote delivers VIA Freeze Quad to Dr. Charles Hunt at the UK Stem Cell Bank located at the National Institute for Biological Standards and Control
|Dr Chris Creasey and Dr charles Hunt||Dr Stuart Milne|
Two of Asymptotes CASE PhD students, Tom Whale (University of Leeds) and Peter Kilbride (UCL) have been invited to participate in the first Organ Banking Hackathon at the global Organ Banking Summit.
Asymptote are organising a Workshop on Cryopreservation of Cell Therapies. To be held as a satellite meeting at the British Society for Gene and Cell Therapy conference, Glasgow, 11th June 2015.
John Morris is co-organising a symposium on “Cryopreservation and Clinical Delivery of Regenerative Medicines” at the annual meeting of the Society for Cryobiology, to be held in Ostrava, Czech Republic July 26 – 29, 2015.
Asymptote presents both a poster and to the UKTI satellite conference at the 18th Takeda Science Foundation Symposium on Bioscience as part of a UKTI trade mission to Japan. We also had the privilege to tour the Centre for iPS Cell Research and Application (CiRA) at Kyoto University and to meet Prof. Takahashi and Prof. Yamanaka. We thank the Takeda, CiRA and the UKTI for making us very welcome in Japan.
|Poster Presentation||Visiting CiRA||With Nobel Prize Winner Shinya Yamanaka|
Mr Stephen Lamb joins Asymptote as the company's new Head of Research and Development
Asymptote launches VIA Freeze range of liquid nitrogen-free controlled rate freezers at ISCT Paris
We are happy to announce that Asymptote has been awarded a Frost & Sullivan Technology Innovation Leadership Award for our work in Cryopreservation
Dr Chris Creasey joins Asymptote as the company's new Chief Scientific Officer
New technology from Asymptote will improve third world vaccine storage and distribution
We will be attending and demonstrating our products at the following exhibitions:
Regener8 Annual Conference, Horizon Conference Centre, Leeds, 2016
Demonstrating our freezing and thawing solutions that fit within the cryochain. Dr Chris Creasey CSO and Alex Nancekievill, Chief Architect, will be in attendance.
World Stem cell and Regenerative Medicine 2016. 18th to 20th May 2016, London
Introducing new products from Asymptote! Please come and visit our booth.
British Association for Crystal Growth (BACG). 13th to 15th July 2014, Leeds
Presenting on "Control of ice nucleation in cryopreservation and freeze drying".
International Society for Cellular Therapy (ISCT). 23rd to 26th April 2014, Paris.
Presenting in the Symposium on "Cryopreservation and biopreservation: Innovation supporting product supply and logistics". We will also be demonstrating the VIA Freeze range of liquid nitrogen-free controlled rate freezers
AMC meeting on cell manufacturing technologies, 6th February 2014, Cardiff
Presenting on "Challenges and solutions in the cryopreservation of ATMPs".
John Morris from Asymptote Ltd. has co-organised the first symposium on Cryopreservation and Good Manufacturing Practice, to be held at the annual meeting of the Society for Cryobiology in Washington D.C.
One of the developing bottlenecks in manufacturing and clinical delivery of cell therapies is successful cryopreservation. The generation and preservation of cells to a level of current Good Manufacturing Process (cGMP) requires a validated, reproducible, and safe method of freezing cells and distributing them through the cold chain to the final user. The Society for Cryobiology and the International Society for Cellular Therapy have arranged a joint symposium on Cryopreservation and Good Manufacturing Practice, to be held at the annual meeting of the Society for Cryobiology in Washington D.C. This meeting will address the integration of cryopreservation in cell therapy manufacture and distribution. This meeting will cover regulatory issues, currently available equipment together with a session at which six companies will share their experiences in taking cryopreserved materials to market.
The annual meeting of the Society for Cryobiology, 28th to 31st July 2013, Washington, USA.
Regener8 Annual Conference 2013, 10th Oct 2013, Leeds. UK